Hormonal
Combination incretin therapies (GLP-1/GIP, GLP-1/Glucagon, or GLP-1/GIP/Glucagon) produce superior weight loss and glycemic control compared to monotherapy GLP-1 receptor agonists by targeting multiple hormonal pathways simultaneously.
If standard GLP-1 drugs (like Ozempic or Saxenda) aren't delivering enough weight loss or metabolic improvement, combination therapies like Tirzepatide (Mounjaro/Zepbound) or Cotadutide target multiple hormones (GLP-1, GIP, Glucagon) to potentially achieve greater weight loss and better blood sugar control. These are typically weekly injections, though oral versions exist. Expect potential gastrointestinal side effects like nausea, which often improve over time. Consult a doctor to see if you qualify for these newer, more potent treatments.
The combination of insulinotropic actions of GIP with the favorable cardiovascular outcomes and weight reduction of GLP-1 may offer superior glycemic control... Compared to a selective GLP-1 receptor agonist, the synergistic action of GIP combined with GLP-1 shows more effective weight loss and reduction in food intake with increased energy expenditure
Why this rating
The review summarizes clinical trials (Phase 2/3) for tirzepatide and cotadutide, but notes that many newer triagonists are still in Phase 1 or animal studies, indicating mixed evidence quality across the category.
Source
New Incretin Combination Treatments under Investigation in Obesity and Metabolism: A Systematic Review
Agni Kakouri et al. · Pharmaceuticals · 2021
DOI 10.3390/ph14090869
More from this paper
- Dual GLP-1/Glucagon receptor agonists (e.g., Cotadutide, Oxyntomodulin) promote weight loss by combining appetite suppression (GLP-1) with increased energy expenditure (Glucagon).Moderate
- Combining GLP-1 receptor agonists with SGLT2 inhibitors produces additive weight loss by reducing caloric intake (GLP-1) and increasing caloric excretion via glucosuria (SGLT2).Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →